Anavex Life Sciences Corporation [AVXL] stock is trading at $4.12, down -0.24%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AVXL shares have gain 7.85% over the last week, with a monthly amount glided 2.49%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Anavex Life Sciences Corporation [NASDAQ: AVXL] stock has seen the most recent analyst activity on December 06, 2022, when Cantor Fitzgerald downgraded its rating to a Neutral and also revised its price target to $11 from $16. Previously, Berenberg started tracking the stock with Buy rating on June 23, 2022, and set its price target to $40. On September 23, 2021, BTIG Research initiated with a Buy rating and assigned a price target of $35 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $17 on December 16, 2020. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $12 as its price target on September 28, 2020. In a note dated June 18, 2019, Janney initiated an Buy rating.
Anavex Life Sciences Corporation [AVXL] stock has fluctuated between $3.25 and $10.45 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Anavex Life Sciences Corporation [NASDAQ: AVXL] shares were valued at $4.12 at the most recent close of the market. An investor can expect a potential return of 166.99% based on the average AVXL price forecast.
Analyzing the AVXL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.29 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.06 points at the first support level, and at 4.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.23, and for the 2nd resistance point, it is at 4.35.
Ratios To Look Out For
For context, Anavex Life Sciences Corporation’s Current Ratio is 15.12. As well, the Quick Ratio is 15.12, while the Cash Ratio is 14.58.
Transactions by insiders
Recent insider trading involved Donhauser Peter D.O., Director, that happened on Jun 14 ’24 when 2835.0 shares were purchased. Director, Thomas Steffen completed a deal on May 15 ’24 to buy 5000.0 shares. Meanwhile, President and CEO MISSLING CHRISTOPHER U sold 73380.0 shares on Mar 28 ’24.
